← Back to Search

Unknown

DONQ52 for Celiac Disease

Verified Trial
Phase 1
Recruiting
Research Sponsored by Chugai Pharmaceutical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
You have been diagnosed with Celiac Disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 246 days

Summary

This trial is testing a new drug called DONQ52 in patients with well-managed celiac disease. The study has two parts: one where patients receive single doses and another where they receive multiple doses. The goal is to see if the drug is safe and well-tolerated.

Who is the study for?
This trial is for people with celiac disease who have mild symptoms or are well-controlled, carry the HLA-DQ2.5 gene, and have been on a gluten-free diet for at least one year. Participants must also have a medical diagnosis confirmed by biopsies and positive serology tests. Those with refractory celiac disease or positive serology markers (tissue transglutaminase-2, deamidated gliadin peptide-IgA/G) cannot join.
What is being tested?
The study is testing DONQ52's safety and how it's processed in the body in two parts: Part A gives patients one dose to see how they react, while Part B gives them multiple doses over time. The effects of DONQ52 will be compared to a placebo (a treatment without any active drug).
What are the potential side effects?
Since this is an investigational drug, specific side effects of DONQ52 are not yet fully known but may include typical drug reactions such as digestive discomfort, headaches, allergic reactions or other unforeseen issues related to medication intake.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 246 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 246 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher
Safety as assessed by Electrocardiograms (ECGs; QT interval, heart rate)
Safety as assessed by Laboratory tests (hematology, blood chemistry, coagulation and urinalysis)
+1 more
Secondary study objectives
Immunogenicity
Pharmacokinetics; Area under the serum concentration time curve [AUC]
Pharmacokinetics; Half life [T1/2]
+3 more

Trial Design

7Treatment groups
Experimental Treatment
Group I: SAD Cohort 4Experimental Treatment2 Interventions
All randomized patients will receive one dose of either DONQ52 Dose D or placebo
Group II: SAD Cohort 3Experimental Treatment2 Interventions
All randomized patients will receive one dose of either DONQ52 Dose C or placebo
Group III: SAD Cohort 2Experimental Treatment2 Interventions
All randomized patients will receive one dose of either DONQ52 Dose B or placebo
Group IV: SAD Cohort 1Experimental Treatment2 Interventions
All randomized patients will receive one dose of either DONQ52 Dose A or placebo
Group V: MAD Cohort 3Experimental Treatment2 Interventions
All randomized patients will receive multiple dose of either DONQ52 Dose G or placebo
Group VI: MAD Cohort 2Experimental Treatment2 Interventions
All randomized patients will receive multiple dose of either DONQ52 Dose F or placebo
Group VII: MAD Cohort 1Experimental Treatment2 Interventions
All randomized patients will receive multiple dose of either DONQ52 Dose E or placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The primary treatment for Celiac Disease is a strict gluten-free diet, which eliminates the ingestion of gluten, thereby preventing the autoimmune response that damages the small intestine. Investigational treatments, such as DONQ52, aim to manage or treat Celiac Disease by targeting specific pathways involved in the immune response to gluten. These treatments may work by inhibiting the activity of tissue transglutaminase (tTG) or modulating the immune system to reduce inflammation and intestinal damage. These mechanisms are crucial for Celiac Disease patients as they offer potential alternatives to a gluten-free diet, which can be challenging to maintain and may not fully alleviate symptoms in all patients.
Outcome measures in coeliac disease trials: the Tampere recommendations.Current status of drugs in development for celiac disease.Treatment failure in coeliac disease: a practical guide to investigation and treatment of non-responsive and refractory coeliac disease.

Find a Location

Who is running the clinical trial?

Chugai PharmaceuticalLead Sponsor
97 Previous Clinical Trials
22,388 Total Patients Enrolled
1 Trials studying Celiac Disease
12 Patients Enrolled for Celiac Disease
Sponsor Chugai Pharmaceutical Co. LtdStudy Directorclinical-trials@chugai-pharm.co.jp
9 Previous Clinical Trials
831 Total Patients Enrolled
1 Trials studying Celiac Disease
12 Patients Enrolled for Celiac Disease

Media Library

DONQ52 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05425446 — Phase 1
Celiac Disease Research Study Groups: SAD Cohort 1, SAD Cohort 2, SAD Cohort 3, SAD Cohort 4, MAD Cohort 1, MAD Cohort 2, MAD Cohort 3
Celiac Disease Clinical Trial 2023: DONQ52 Highlights & Side Effects. Trial Name: NCT05425446 — Phase 1
DONQ52 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05425446 — Phase 1
Celiac Disease Patient Testimony for trial: Trial Name: NCT05425446 — Phase 1
~18 spots leftby Nov 2025